Modified Alpha1PI for Hematopoietic Cell Subset Mobilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic applications of α1 proteinase inhibitor (α1PI) are limited to treating inherited deficiency and do not effectively mobilize lymphoid-lineage or myeloid-lineage maturing cells, and there is a need for recombinant α1PI forms that consider its conformation-dependent function for targeted cell subset mobilization.
Innovation Solution
Modified α1PI forms, produced through site-directed mutagenesis or proteolysis, are used to control the phenotypic composition of hematopoietic stem cell-derived cells, with specific modifications aimed at treating conditions like HIV-1 infection, leukemia, and autoimmune diseases by altering biological activity and receptor binding properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional α1PI is used for treating inherited deficiency, then the deficiency condition is addressed, but it does not effectively mobilize lymphoid-lineage or myeloid-lineage maturing cells
Solution Approach 1:
The patent applies site-directed mutagenesis to introduce specific amino acid substitutions at defined positions (e.g., Lys30Arg, Lys33Arg, Lys36Arg) in the α1PI molecule. These localized modifications alter the protein's conformation and receptor binding properties, enabling it to mobilize specific cell subsets (lymphoid-lineage or myeloid-lineage) while maintaining its ability to treat inherited deficiency. This local quality change allows the same protein to perform multiple specialized functions.
Solution Approach 2:
The patent systematically varies amino acid substitutions at specific positions (Lys30, Lys33, Lys36) to create different α1PI variants with distinct biological activities. By changing these molecular parameters, the patent generates a family of proteins with tailored conformational properties and receptor binding characteristics, enabling selective mobilization of different cell subsets while maintaining therapeutic efficacy for inherited deficiency.
2Adaptability or versatility
If recombinant α1PI forms are developed for targeted cell subset mobilization, then adaptability for treating diverse conditions is improved, but manufacturing complexity increases
Solution Approach 1:
The patent divides the α1PI protein structure into specific functional regions by targeting particular amino acid positions (Lys30, Lys33, Lys36) for modification. This segmentation approach allows independent optimization of different functional domains, enabling the creation of variants with specific conformational properties and receptor binding characteristics while maintaining the overall protein framework and simplifying the manufacturing process.
Solution Approach 2:
The patent creates a universal platform of α1PI variants that can treat multiple diverse conditions (HIV-1 infection, leukemia, autoimmune diseases) through conformation-dependent functions. By developing a family of proteins with varying amino acid substitutions at key positions, the patent achieves multi-functionality where a single manufacturing platform can produce variants tailored to different therapeutic needs, reducing overall manufacturing complexity.
Data Source
AI summary
A previously unrecognized fundamental property of α1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified α1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with Human Immunodeficiency Virus-1 (HIV-1) infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of α1PI with its receptors, cell surface Human Leucocyte Elastase (HLEcs) and Lipoprotein Receptor-related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of α1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.